HOME › FORMULAS › INGREDIENTS › AKKERMANSIA MUCINIPHILA

PROBIOTIC & FIBRE
A. muciniphila
pasteurised, strain MucT
IN 1 OF THE 29 FORMULAS NO AUTHORISED CLAIM

Akkermansia muciniphila

A gut bacterium, served pasteurised. It is in one of our formulas, Digestion & microbiome, and it carries no authorised EU health claim. What it does have is an EU authorisation as a novel food, which is a safety approval, not a claim.

FORM WE USE Pasteurised, strain MucTPasteurised MucT
NRV None, not a nutrientNone
OUR RANGE 10 billion CFU, in one formula
EFSA UPPER LIMIT Not established
APPEARS IN 1 formula
AUTHORISED CLAIMS None under Reg. 432/2012

WHAT WE ARE ALLOWED TO SAY

No authorised claim. A safety approval instead.

There is no health claim for Akkermansia on the EU register, so there is no wording to quote here. What it has is an authorisation as a novel food: EFSA assessed pasteurised Akkermansia muciniphila for safety in 2021, and it was authorised in the EU. That lets it be sold as a food. It says nothing about what it does for you, and we are not going to write a sentence that sounds as if it did.There is no health claim for Akkermansia on the EU register. It is authorised as a novel food, which is a safety approval, not permission to say what it does for you.

AND WHAT THAT MEANS

Our file describes how it is thought to work, on the mucus layer of the gut lining, on the gut barrier and on glucose and fat metabolism. None of that is an authorised claim, so you will not read it here as a promise. In Digestion & microbiome, the one authorised claim on the page belongs to zinc, not to the bacteria.

WHY PASTEURISED MucT

One form, and the authorisation names it.

The EU authorisation our file records does not cover Akkermansia in general. It covers one strain, MucT, in pasteurised form, and that is the form on file. So there is no form to choose between, and no form argument to make. Our file also records it as stable in liquid, soluble in water and neutral in taste, which is what lets it be poured in pulses at all.

WHAT IT ISA bacterium of the gut lining

Our file describes it as a bacterium that lives on the mucus of the gut lining, breaks that mucus down and prompts its renewal. The mechanisms studied involve a surface protein, Amuc_1100, the tight junctions of the gut barrier and short-chain fatty acids such as propionate and acetate. A mechanism, not a claim.

WHY PASTEURISEDThe authorised form

Pasteurised strain MucT is the form named in the EU authorisation on file. The two other strains in the formula are live cultures; this one is not, and it is recorded as leaving the body through the gut rather than being absorbed.

HOW FASTWeeks, not hours

Our file puts the onset at 8 to 12 weeks and marks the evidence as limited. That fits a base formula held for at least eight weeks, not a dose you would expect to feel the same morning.

THE HONEST VERSION

Our file on Akkermansia is a short one. It has the authorised strain, the mechanism and the EFSA safety opinion, but deeper research on it is still marked as pending, and the number of the EU regulation behind the authorisation is not written the same way in every record. Until that is settled, the reference we cite on this page is the EFSA opinion itself.Our file on Akkermansia is still a short one, and the regulation number behind the authorisation is not consistent across our records. Until it is, we cite the EFSA opinion itself.

WHERE IT APPEARS

One of the twenty-nine carries Akkermansia.

It sits in Digestion & microbiome, next to two live bacterial strains, inulin, GOS and zinc, taken 15 – 30 minutes before breakfast. Its dose is recorded as 10 billion CFU, and that figure is under review against the authorisation, which you can read about just below. We would rather tell you that than leave it out.

FORMULATYPEDOSEWINDOWWHY IT IS IN THERE
Digestion & microbiome CORE 10 billion CFU
10 billion CFU Morning Morning · The pasteurised strain, next to two live strains and two prebiotic fibres, before breakfast

THE CEILING

No upper limit. An authorised amount.

EFSA has not set a tolerable upper intake level for Akkermansia, so there is no ceiling to draw here. Its novel food authorisation does come with conditions of use, which our file records as up to 3.4 × 10⁹ cells a day for adults. The dose in our formula is recorded as 10 billion CFU. That is a different unit and, read at face value, about three times the authorised amount. We have flagged it for review, and this page will say what the review finds.EFSA has not set an upper intake level. The novel food authorisation allows up to 3.4 × 10⁹ cells a day for adults, and our recorded dose of 10 billion CFU is under review against it.

WHAT IS SETConditions of use, not a limit

The EFSA opinion assessed safety and set conditions of use for adults. Our file records no time limit on use, so there is no built-in stop for this ingredient.

UNDER REVIEWOur dose against the authorisation

10 billion CFU in the formula, up to 3.4 × 10⁹ cells a day in the authorisation. Until the two are reconciled, we do not say the formula meets that condition.

NEVER FORWho should not take it

Ask a health professional first if you are immunocompromised or have had recent abdominal surgery. Not for children under 3 without medical supervision. The formula that carries it is not for SIBO (small intestinal bacterial overgrowth) or severe immunosuppression. And the usual three: do not exceed the daily dose, it does not replace a varied and balanced diet, and keep it out of reach of young children.

WHAT IT REACTS WITH

No documented pairs yet.

Akkermansia is one of the 140 ingredients in our library, so it has 139 possible partners. None of them is among the 443 pairs we have documented so far, and no medicine is on file against it either.

NOT CHECKED YETOther ingredients

No pair with another ingredient is documented for Akkermansia, including the two strains and the two fibres it shares a formula with. That is an open question, not a clean result.

DECLARED ALLERGENSNone on file

Our file records no allergen that must be declared under Regulation (EU) 1169/2011, Annex II, no documented intolerance and no known dietary restriction for Akkermansia itself.

NOT CHECKED YETMedicines

No interaction with a medicine is on file for Akkermansia, and our pharmacokinetic file found nothing on liver enzymes. A check against drug interaction databases is still pending, so if you take medication, ask before you start.

WHAT WE HAVE NOT CHECKED YET

443 of the 9,730 possible pairs in our library are documented, which is 4.55%, and none of them involves Akkermansia. The rest are not "safe", they are simply unchecked, and we would rather write that down than let the number look like a badge.443 of the 9,730 possible pairs in our library are documented, which is 4.55%, and none of them involves Akkermansia. The rest are not safe, they are simply unchecked.

SOURCES

Everything on this page, with its reference.

NOVEL FOOD EFSA Journal 2021;19(9):6780 — Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283 safety assessment and conditions of use, not a claim
REGULATION Regulation (EU) 432/2012 — the EU list of authorised health claims Akkermansia not included
EFSA EFSA — tolerable upper intake level for Akkermansia muciniphila not established
REGULATION Regulation (EU) 1169/2011, Annex II — allergens that must be declared none declarable
REGULATION Directive 2002/46/EC, Art. 6.3 — labelling of food supplements standard label warnings

Reviewed by VION nutrition team · last reviewed 16 September 2026

140 INGREDIENTS · 64 IN USE TODAY

Every one of them has a page like this.

What it is, what we are allowed to say about it, which formulas carry it, what it reacts with and where each of those statements comes from. No proprietary blends, no hidden amounts.